The Saskatchewan government says it will publicly cover the cystic fibrosis drug Alyftrek for eligible patients in the province, expanding treatment options for children and adults living with the genetic lung and digestive disease.
Who qualifies and how it works
According to the Saskatchewan Ministry of Health, Alyftrek will be available to patients aged six and older who meet the drug’s medical criteria. The ministry said the treatment is effective for people with one of 266 genetic mutations that cause cystic fibrosis (CF).
The government did not release an exact start date for coverage in its statement, but said the decision follows a recommendation by Health Canada in July 2025 and pricing negotiations concluded the previous month.
Why the move matters in Saskatchewan
Cystic fibrosis is a hereditary condition that damages the lungs and the digestive system. Nationally, the province said there are more than 4,500 Canadians living with CF, and nearly 150 of them reside in Saskatchewan.
Access to new modulators such as Alyftrek can improve lung function and quality of life for people with particular CF gene mutations by targeting the underlying protein dysfunction that causes the disease.
“Our government is pleased to cover the cost of this new treatment for Saskatchewan patients with cystic fibrosis,” said Saskatchewan Health Minister Jeremy Cockrill in a statement. “Alyftrek has been shown to improve quality of life in patients with CF, so expanding coverage puts CF patients first by helping them to lead healthier lives.”
What patients and families should do next
The ministry urged patients with cystic fibrosis, or parents of children with the condition, to speak with their doctor if they think they may benefit from Alyftrek.
Clinicians will need to determine whether a patient’s specific genotype is covered by the drug’s indication and whether medical criteria are met. The province’s announcement indicates coverage is limited to those meeting the drug’s approved mutation list and other clinical criteria.
- Age eligibility: six years and older.
- Genetic eligibility: one of 266 CF-causing mutations.
- Provincial count: nearly 150 people with CF live in Saskatchewan.
Timeline and policy context
Health Canada recommended Alyftrek in July 2025. The province’s coverage followed recent pricing negotiations, a standard step in making new drugs publicly available.
Provincial drug coverage decisions typically involve assessment of clinical benefit, safety, and negotiated pricing. The ministry’s statement framed the decision as putting CF patients first by expanding treatment choices that can improve quality of life.
Practical considerations for families
Families should confirm with their CF clinic or primary-care provider whether genotyping has been completed; knowing the specific mutation is essential to determine eligibility for Alyftrek. If genotyping has not been performed, clinicians can arrange appropriate testing and discuss next steps.
| Item | Detail |
|---|---|
| Drug | Alyftrek |
| Age eligible | 6 years and older |
| Genetic eligibility | One of 266 CF-causing mutations |
| Estimated people with CF in SK | Nearly 150 |
| Federal recommendation | July 2025 |
As with any new treatment, patients and caregivers will want to discuss potential side effects, monitoring needs and how Alyftrek fits into the broader care plan. Local CF clinics remain the primary resource for these conversations.
For many Saskatchewan families living with cystic fibrosis, provincial coverage removes a major barrier to accessing treatment. The government’s announcement aligns with a broader trend of provinces updating formularies after Health Canada approvals and subsequent pricing discussions.
Those seeking more information should contact their health-care provider or the Saskatchewan Ministry of Health for details on how to access the drug under provincial coverage.
